AN INSIGHT OF FDA-APPROVED DRUGS FOR THE MANAGEMENT OF AGING-RELATED DISORDER - A IN SILICO STUDY

Skeletal muscle (SM) is the most complex and plastic tissue of the human body. Movement, postural support, breathing, and thermogenesis are important functions of SM. Muscle mass reduction is a common side effect of human aging. The growth factor myostatin (MSTN) appears to play a key role in aging-related muscle function decreases. Targeting MSTN might help people live longer by preventing SM alterations associated with aging. Therefore, in the present study, FDA-approved drugs were screened against MSTN to find the best drugs against MSTN for the management of the aging disease. In this re-gard, screening, docking, and molecular dynamics simulation were used. Based on structure-based vir-tual screening and free energy of bind, we select the top five drugs mentioned in this article. Two drugs were analyzed in-depth namely, Sonidegib and Revefenacin showing free energy of binding-10.95 and-12.03 kcal/mol respectively with MSTN. Further, these complex was forwarded for molecular dynamics simulation to check the structural stability during 100ns, which was found to be more stable. As a con-cluding remark, Sonidegib and Revefenacin can be considered for further designing of new drugs against MSTN for the treatment of aging-related disorders.